Hexarelin the science.

Hexarelin (examorelin) is a synthetic six-amino-acid peptide closely related to GHRP-6. Like other GHRPs, it activates the growth-hormone-secretagogue receptor (GHS-R1a) to stimulate GH release. What distinguishes it in the research literature is an additional reported interaction with CD36, a scavenger receptor expressed in cardiovascular tissue, which has made hexarelin a tool of interest in cardiac and vascular models.

The research interest lies both in its potency as a GH secretagogue and in its CD36-linked actions that are studied independently of GH release. Hexarelin is an investigational compound, not an approved medicine.

Hexarelin research spans two receptor systems:

• GHS-R1a activation — binding the ghrelin receptor on pituitary somatotrophs is studied for how it triggers GH release.
• CD36 interaction — the scavenger-receptor pathway is examined in cardiovascular tissue models, distinct from the GH axis.
• Cardiac tissue models — preclinical work has studied hexarelin’s effects on cardiac function and protection in animal systems.

Hexarelin has both preclinical and early-phase human research:

• Intranasal GH-release study (1994). Research in Clinical Endocrinology reported GH-releasing activity following intranasal administration of hexarelin in human subjects.
• Long-term GH-status study (1998). A study in the Journal of Clinical Endocrinology & Metabolism examined GH status during extended hexarelin administration, including changes in responsiveness over time.

These human studies are early-phase and investigational. Hexarelin is not FDA-approved, and this material is supplied for research use only.

Hexarelin is an investigational GH secretagogue. Published evidence includes early-phase human studies alongside preclinical cardiovascular and GH-axis work, but it is not FDA-approved and no approved indication, dosing, or therapeutic claim applies. Hexarelin is supplied strictly as a research material for laboratory investigation.